pi3k  (Santa Cruz Biotechnology)

Journal: Journal of Animal Science and Biotechnology

Article Title: ZBED6 deletion activates FNDC1 -mediated PI3K/AKT and MAPK/ERK1/2 signaling pathways to promote myogenesis in pigs

doi: 10.1186/s40104-026-01504-w

Figure Lengend Snippet: ZBED6 deletion activates FNDC1 -mediated PI3K/AKT and MAPK/ERK1/2 signaling pathways. A RNA-seq data from ZBED6-deficient pigs, ZBED6 knockout myoblasts and myotubes, and FNDC1 knockdown C2C12 cells were comprehensively analyzed to screen downstream signaling pathways. B Protein expression levels and statistical analysis of p-AKT, AKT, p-mTOR and mTOR in WT and ZBED6 −/− pigs, n = 3 pigs/genotype. C and D Protein expression levels and statistical analysis, n = 3 pigs/genotype. E and F Protein expression levels and statistical analysis of p-mTOR, mTOR, p-AKT, AKT, p-ERK1/2 and ERK1/2, n = 3 independent cell-culture experiments. Data are expressed as mean ± SEM. In (B), and (D), the P values were determined by two-tailed Student's t -tests. In (F), the P values were determined by two-way ANOVA followed by Sidak's multiple comparisons test, different letters (a, b and c) between bars indicate P < 0.05

Article Snippet: Primary porcine skeletal muscle satellite cells were treated with 10 μmol/L LY294002, a PI3K inhibitor (MCE, HY-10108), or 1 μmol/L SCH772984, an ERK1/2 inhibitor (MCE, HY-50846).

Techniques: Protein-Protein interactions, RNA Sequencing, Knock-Out, Knockdown, Expressing, Analysis, Cell Culture, Two Tailed Test

Journal: Journal of Animal Science and Biotechnology

Article Title: ZBED6 deletion activates FNDC1 -mediated PI3K/AKT and MAPK/ERK1/2 signaling pathways to promote myogenesis in pigs

doi: 10.1186/s40104-026-01504-w

Figure Lengend Snippet: Inhibition of PI3K/AKT and MAPK/ERK1/2 pathways reduces the effects of the ZBED6-FNDC1 axis on myogenesis. A and B representative immunofluorescence staining for EdU ( A ) and percentage of EdU positive cells ( B ) in ZBED6 knockdown primary porcine skeletal muscle satellite cells treated with SCH772984, n = 3 independent cell-culture experiments. C and D . representative immunofluorescence staining for EdU ( C ) and percentage of EdU positive cells ( D ) in ZBED6 knockdown primary porcine skeletal muscle satellite cells treated with LY294002, n = 3 independent cell-culture experiments. E and F representative immunofluorescence staining for MYHC ( E ) and fusion index ( F ) in ZBED6 knockdown primary porcine skeletal muscle satellite cells treated with SCH772984, n = 3 independent cell-culture experiments. G and H representative immunofluorescence staining for MYHC ( G ) and fusion index ( H ) in ZBED6 knockdown primary porcine skeletal muscle satellite cells treated with LY294002, n = 3 independent cell-culture experiments. Data are represented as mean ± SEM. In (B), (D), (F), and (H), the P values were determined by two-way ANOVA followed by Sidak's multiple comparisons test, different letters (a and b) between bars indicate P < 0.05

Article Snippet: Primary porcine skeletal muscle satellite cells were treated with 10 μmol/L LY294002, a PI3K inhibitor (MCE, HY-10108), or 1 μmol/L SCH772984, an ERK1/2 inhibitor (MCE, HY-50846).

Techniques: Inhibition, Immunofluorescence, Staining, Knockdown, Cell Culture

Journal: Frontiers in Oncology

Article Title: NONO modulates tumorigenesis and metastatic potential of lung squamous cell carcinoma

doi: 10.3389/fonc.2026.1574103

Figure Lengend Snippet: The effect of NONO on the expression of proteins related to the PI3K/AKT signaling pathway in LUSC cells. (A) NONO-depleted in LUSC can inhibit the activation of PI3K/AKT. (B) Statistical analysis of protein expression. (C) Exogenous expression of NONO in LUSC cells can promote the phosphorylation of PI3K/AKT and activate downstream protein expression. (D) Statistical analysis of protein expression. (Statistical differences between groups were determined using Two-way ANOVA, with a significance level of P < 0.05(notes: * P < 0.05; ** P < 0.01; *** P < 0.001;**** P < 0.0001, ns, not significant.) Data are presented as mean ± SD (n = 3).

Article Snippet: PI3K inhibitor LY294002 (Cat. No. HY-10108) and PI3K agonist UCL-TRO-1938 (Cat. No. HY-154848) were purchased from MCE.

Techniques: Expressing, Activation Assay, Analysis, Phospho-proteomics

Journal: Frontiers in Oncology

Article Title: NONO modulates tumorigenesis and metastatic potential of lung squamous cell carcinoma

doi: 10.3389/fonc.2026.1574103

Figure Lengend Snippet: NONO depletion modulates the responsiveness of the PI3K/AKT pathway toward PI3K agonists or inhibitors. (A) CCK-8 assay for the effects of PI3K inhibitor on LUSC cell proliferation. (B) CCK-8 assay for the effects of PI3K agonist on LUSC cell proliferation. (C) Effects of PI3K agonist or inhibitor on colony-forming ability of LUSC cells. (D) Regulatory effects of PI3K agonist or inhibitor on cell-cycle progression in LUSC cells. (E) Regulatory effects of PI3K inhibitor or agonist on apoptosis in LUSC cells. (F) Western blot was used to examine changes in PI3K/AKT signaling axis protein levels in LUSC cells treated with 10 μM PI3K inhibitor LY294002 for 3 hours. And statistical analysis of protein expression. (G) The influence of PI3K agonist UCL-TRO-1938 (10 μM, treatment for 20 min) on PI3K/AKT pathway proteins in NONO-silenced LUSC cells. And statistical analysis of protein expression. (Statistical differences between groups were determined using Two-way ANOVA, with a significance level of P < 0.05(notes: * P < 0.05; ** P < 0.01; *** P < 0.001;**** P < 0.0001, ns, not significant.).Data are presented as mean ± SD (n = 3).

Article Snippet: PI3K inhibitor LY294002 (Cat. No. HY-10108) and PI3K agonist UCL-TRO-1938 (Cat. No. HY-154848) were purchased from MCE.

Techniques: CCK-8 Assay, Western Blot, Analysis, Expressing

Journal: Frontiers in Oncology

Article Title: NONO modulates tumorigenesis and metastatic potential of lung squamous cell carcinoma

doi: 10.3389/fonc.2026.1574103

Figure Lengend Snippet: The effect of NONO on the expression of proteins related to the PI3K/AKT signaling pathway in LUSC cells. (A) NONO-depleted in LUSC can inhibit the activation of PI3K/AKT. (B) Statistical analysis of protein expression. (C) Exogenous expression of NONO in LUSC cells can promote the phosphorylation of PI3K/AKT and activate downstream protein expression. (D) Statistical analysis of protein expression. (Statistical differences between groups were determined using Two-way ANOVA, with a significance level of P < 0.05(notes: * P < 0.05; ** P < 0.01; *** P < 0.001;**** P < 0.0001, ns, not significant.) Data are presented as mean ± SD (n = 3).

Article Snippet: PI3K inhibitor LY294002 (Cat. No. HY-10108) and PI3K agonist UCL-TRO-1938 (Cat. No. HY-154848) were purchased from MCE.

Techniques: Expressing, Activation Assay, Analysis, Phospho-proteomics

Journal: Frontiers in Oncology

Article Title: NONO modulates tumorigenesis and metastatic potential of lung squamous cell carcinoma

doi: 10.3389/fonc.2026.1574103

Figure Lengend Snippet: NONO depletion modulates the responsiveness of the PI3K/AKT pathway toward PI3K agonists or inhibitors. (A) CCK-8 assay for the effects of PI3K inhibitor on LUSC cell proliferation. (B) CCK-8 assay for the effects of PI3K agonist on LUSC cell proliferation. (C) Effects of PI3K agonist or inhibitor on colony-forming ability of LUSC cells. (D) Regulatory effects of PI3K agonist or inhibitor on cell-cycle progression in LUSC cells. (E) Regulatory effects of PI3K inhibitor or agonist on apoptosis in LUSC cells. (F) Western blot was used to examine changes in PI3K/AKT signaling axis protein levels in LUSC cells treated with 10 μM PI3K inhibitor LY294002 for 3 hours. And statistical analysis of protein expression. (G) The influence of PI3K agonist UCL-TRO-1938 (10 μM, treatment for 20 min) on PI3K/AKT pathway proteins in NONO-silenced LUSC cells. And statistical analysis of protein expression. (Statistical differences between groups were determined using Two-way ANOVA, with a significance level of P < 0.05(notes: * P < 0.05; ** P < 0.01; *** P < 0.001;**** P < 0.0001, ns, not significant.).Data are presented as mean ± SD (n = 3).

Article Snippet: PI3K inhibitor LY294002 (Cat. No. HY-10108) and PI3K agonist UCL-TRO-1938 (Cat. No. HY-154848) were purchased from MCE.

Techniques: CCK-8 Assay, Western Blot, Analysis, Expressing